Edwards Lifesciences

Worldwide Artificial Organ and Bionics Industry to 2025 - Advantageous in Comparison Prosthetics Presents Opportunities

Tuesday, April 13, 2021 - 7:15pm

This has been a major boost for the artificial organ bionics market, as the patients cannot afford to wait in queue since the stakes are very high.

Key Points: 
  • This has been a major boost for the artificial organ bionics market, as the patients cannot afford to wait in queue since the stakes are very high.
  • Bionics and artificial organs are able to cater to the needs of those in need of organ transplantations and replacements.
  • In February 2020, Ekso Bionics Holdings, Inc. collaborated with Kindred Healthcare, LLC to pilot EksoNR - a robotic exoskeleton, in their long-term acute care hospitals.\n2.
  • In April 2019, Edwards Lifesciences Corporation acquired CAS Medical Systems, Inc., a medical technology company dedicated to non-invasive brain and tissue oxygenation monitoring.\n3.

Edwards Lifesciences To Host Earnings Conference Call On April 20, 2021

Tuesday, April 13, 2021 - 12:05pm

b'IRVINE, Calif., April 13, 2021 /PRNewswire/ -- Edwards Lifesciences (NYSE: EW) plans to announce its operating results for the quarter ended March 31, 2021 after the market closes on Tuesday, April 20, 2021, and will host a conference call at 5:30 p.m.

Key Points: 
  • b'IRVINE, Calif., April 13, 2021 /PRNewswire/ -- Edwards Lifesciences (NYSE: EW) plans to announce its operating results for the quarter ended March 31, 2021 after the market closes on Tuesday, April 20, 2021, and will host a conference call at 5:30 p.m.
  • ET that day to discuss those results.\nTo participate in the conference call, dial (877) 704-2848 or (201) 389-0893.
  • For 72 hours following the call, an audio replay can be accessed by dialing (877) 660-6853 or (201) 612-7415 and using conference number 13717235.
  • For more information, visit Edwards.com and follow us on Facebook, Instagram, LinkedIn, Twitter and YouTube.\nEdwards, Edwards Lifesciences, and the stylized E logo are trademarks of Edwards Lifesciences Corporation.

Global Artificial Organ and Bionics Market (2020 to 2025) - by Type, Technology, End-user and Geography - ResearchAndMarkets.com

Thursday, April 8, 2021 - 1:48pm

In February 2020, Ekso Bionics Holdings, Inc. collaborated with Kindred Healthcare, LLC to pilot EksoNR - a robotic exoskeleton, in their long-term acute care hospitals.

Key Points: 
  • In February 2020, Ekso Bionics Holdings, Inc. collaborated with Kindred Healthcare, LLC to pilot EksoNR - a robotic exoskeleton, in their long-term acute care hospitals.
  • In April 2019, Edwards Lifesciences Corporation acquired CAS Medical Systems, Inc., a medical technology company dedicated to non-invasive brain and tissue oxygenation monitoring.
  • The report offers a comprehensive evaluation of the Global Artificial Organ and Bionics Market.
  • The report also contains the competitive analysis using IGR Competitive Quadrant, the analyst's proprietary competitive positioning tool.

Heart Valve Disease Awareness Day Campaign Celebrates Fifth Anniversary with Focus on Health Disparities

Monday, February 22, 2021 - 2:30pm

WASHINGTON, Feb. 22, 2021 /PRNewswire/ -- Today, Monday, February 22, more than 90 national organizations and thousands of patient advocates will recognize the fifth anniversary of the annual Heart Valve Disease Awareness Day ("Valve Disease Day") and the importance of addressing the disproportionate impact heart valve disease (HVD) has on America's Black communities.

Key Points: 
  • WASHINGTON, Feb. 22, 2021 /PRNewswire/ -- Today, Monday, February 22, more than 90 national organizations and thousands of patient advocates will recognize the fifth anniversary of the annual Heart Valve Disease Awareness Day ("Valve Disease Day") and the importance of addressing the disproportionate impact heart valve disease (HVD) has on America's Black communities.
  • Many Valve Disease Day awareness efforts this year have focused on highlighting the disparities in HVD diagnosis and treatment that Black Americans face.
  • As many as 11 million Americans have heart valve disease, yet general awareness of the disease is low.
  • The 2021 Heart Valve Disease Awareness Day campaign was made possible with support from Edwards Lifesciences Foundation and Abbott.

Heart Valve Disease Awareness Day Campaign Celebrates Fifth Anniversary with Focus on Health Disparities

Tuesday, February 16, 2021 - 2:35pm

Many Valve Disease Day awareness efforts this year are focused on highlighting the disparities in HVD diagnosis and treatment that Black Americans face.

Key Points: 
  • Many Valve Disease Day awareness efforts this year are focused on highlighting the disparities in HVD diagnosis and treatment that Black Americans face.
  • As many as 11 million Americans have heart valve disease, yet general awareness of the disease is low.
  • "As many as 11 million Americans have heart valve disease, yet general awareness of the disease is low.
  • The 2021 Heart Valve Disease Awareness Day campaign was made possible with support from Edwards Lifesciences Foundation and Abbott.

Insights on the Transcatheter Treatment: Procedures and Heart Valve Global Market to 2025 - Key Drivers and Restraints

Friday, February 12, 2021 - 2:45pm

Europe is the second-largest market after the U.S., and there are many established and early-stage companies that are working to enter the European TAVR market by developing improved transcatheter heart valve devices.

Key Points: 
  • Europe is the second-largest market after the U.S., and there are many established and early-stage companies that are working to enter the European TAVR market by developing improved transcatheter heart valve devices.
  • With regard to the European transcatheter treatment device market, it is growing mainly due to improved healthcare infrastructure, increasing prevalence of heart disease, improving diagnosis rates, and growing demand for minimally invasive and catheter-based treatment options.
  • Additionally, the increased patient population and improving diagnosis rate are likely to increase the demand for TAVR/TAVI and TMVR procedures within the region.
  • Japan is an established market in Asia-Pacific, while China and India are emerging markets that are growing rapidly.

Worldwide Transcatheter Treatment Procedures and Heart Valve Industry to 2025 - Major Developments Influencing the Market - ResearchAndMarkets.com

Thursday, February 11, 2021 - 11:56am

The "Transcatheter Treatment: Procedures and Heart Valve Market" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Transcatheter Treatment: Procedures and Heart Valve Market" report has been added to ResearchAndMarkets.com's offering.
  • Transcatheter treatment includes procedure types such as TAVR, TAVI, TMVR and TMVI.
  • Transcatheter procedure approaches include transfemoral, transapical and transaortic procedures.
  • This report is an analytical business tool with the primary purpose of providing a thorough evaluation of the global market for transcatheter treatment for heart valve diseases.

Alleviant Medical Receives Breakthrough Device Designation From FDA for Transcatheter Technology

Monday, January 25, 2021 - 3:16pm

Alleviant Medical Inc. , a privately-held medical device company, today announced that the US Food and Drug Administration (FDA) has granted the company a Breakthrough Device designation for its transcatheter technology.

Key Points: 
  • Alleviant Medical Inc. , a privately-held medical device company, today announced that the US Food and Drug Administration (FDA) has granted the company a Breakthrough Device designation for its transcatheter technology.
  • By utilizing a no-implant interatrial shunt approach, the Alleviant Medical technology offers the option for a simple, minimally-invasive procedure for heart failure patients.
  • We appreciate the rigorous review by the FDA and their designation of our technology as a Breakthrough Device.
  • Alleviant Medical is a privately held medical device company that is dedicated to developing novel therapies for patients suffering from heart failure.

Edwards Lifesciences To Host Earnings Conference Call On January 27, 2021

Wednesday, January 13, 2021 - 12:05pm

IRVINE, Calif., Jan. 13, 2021 /PRNewswire/ --Edwards Lifesciences (NYSE: EW) plans to announce its operating results for the quarter ended December 31, 2020 after the market closes on Wednesday, January 27, 2021, and will host a conference call at 5:00 p.m.

Key Points: 
  • IRVINE, Calif., Jan. 13, 2021 /PRNewswire/ --Edwards Lifesciences (NYSE: EW) plans to announce its operating results for the quarter ended December 31, 2020 after the market closes on Wednesday, January 27, 2021, and will host a conference call at 5:00 p.m.
  • For 72 hours following the call, an audio replay can be accessed by dialing (877) 660-6853 or (201) 612-7415 and using conference number 13714408.
  • Edwards Lifesciences, is the global leader of patient-focused innovations for structural heart disease and critical care monitoring.
  • Edwards, Edwards Lifesciences, and the stylized E logo are trademarks of Edwards Lifesciences Corporation.

Foldax Named Cardiovascular Device Company of the Year by MedTech Outlook

Tuesday, October 13, 2020 - 1:00pm

Foldax announced today that it has been selected as Company of the Year among 10 cardiovascular device company finalists by MedTech Outlook Magazine.

Key Points: 
  • Foldax announced today that it has been selected as Company of the Year among 10 cardiovascular device company finalists by MedTech Outlook Magazine.
  • Foldax was honored for its innovativeTria heart valve, the first biopolymer heart valve to receive FDA approval for a U.S. clinical trial.
  • Foldax has reinvented every aspect of the artificial heart valve from material to design to manufacturing to develop surgical and transcatheter valves designed to last a lifetime that address historical tradeoffs.
  • We take pride in honoring Foldax as our Company of the Year among 10 finalists specializing in Cardiovascular Device Solutions, said Alex Dsouza, Managing Editor of MedTech Outlook.